AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
Novo Nordisk and Hims & Hers end their legal battle and team up to offer FDA-approved Ozempic and Wegovy (injections and pills) on the Hims platform. Hims shifts its focus to branded GLP-1s with limited compounded options. Shares surge.
Novo Nordisk is set to sell its popular weight-loss drugs like Wegovy on Hims & Hers platform soon, surprising many after a recent lawsuit over copycat versions. This could boost access and help both companies in the competitive obesity market.
GoodRx partners with Eli Lilly to help employers subsidize Zepbound KwikPen at a $449 monthly price. The new Employer Direct program reduces out-of-pocket costs for workers without overhauling health benefits.
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
Novo Nordisk slashes list prices for Wegovy, Ozempic & Rybelsus to $675/month starting Jan 2027—50% cut for Wegovy. Helps high-deductible plans, but BofA sees little threat to Eli Lilly’s GLP-1 lead.